Randomized Controlled Clinical Stardy on Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Academy of Chinese Medical Sciences
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A

Criteria

Inclusion Criteria:

1. Idiopathic blepharospasm met the diagnostic criteria.

2. The age ranges from 18 to 80 years.

3. Liver Yang deficiency,mixed syndrome of cold and heat.

4. Signed Informed consent

Exclusion Criteria:

1. Secondary blepharospasm due to keratoconjunctivitis, trichiasis, and blepharitis.

2. Open eyelid disuse.

3. hemifacial spasm.

4. The patient had undergone eye surgery in the previous 6 months.

5. Allergic to the ingredients in the medicine.

6. Corneal lenses were worn during the study.

7. A woman who is pregnant or breastfeeding.

8. Combined with cardiovascular, cerebrovascular,Liver and kidney function, hematopoietic system serious primary disease, mental patients, combined with stroke patients.

9. At the same time, use drugs that interfere with the evaluation of drug efficacy.

10. Idiopathic blepharospasm is treated with other drugs.